Intelligent Oncology
Predicting cancer treatment response before therapy begins
CHOSA Oncology Presented at Aktiedagarna Stockholm
The presentaiton included it approach to precision medicine highlighting CHOSA's innovative strategies and upcoming milestones.Latest Releases
CHOSA Files Patent for Platinum-Immunotherapy Combination Predictor
New PCT application expands Platin-DRP™ to predict patient response to platinum chemotherapy and PD-1/PD-L1 immunotherapy combinations (25 June 2025).
CHOSA to Present Platin-DRP™ Data in Breast Cancer at ESMO
New breast cancer findings support the gene signature’s ability to predict response to carboplatin treatment (08 August 2025).We provide a safe and more effective solution for patients in need of platin-treatment
Platin-DRP™
Our patented Platin-DRP™ analyzes 205 key genes in a patient’s tumor to predict their response to cisplatin and carboplatin, enabling personalized treatment plans to oncology patients. We have shown that our innovative technology not only improves survival rates, but also enables doctors to avoid overtreatment of toxic platin to non-responsding patients.
LiPlaCis®
A new formulation of cisplatin in a liposome aimed for a solution to cisplatin treatment by targeting tumors directly, reducing harmful side effects. Using a specialized liposome delivery system, LiPlaCis® releases cisplatin precisely where it's needed most - at the tumor site - providing safer and more effective cancer care.
Key Opinion Leaders
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our Platin-DRP™ and advances our mission toward precision oncology.
Dr. Fred Hirsch